Platelet rich plasma for the management of urogynecological disorders: the current evidence

Curr Opin Obstet Gynecol. 2022 Dec 1;34(6):396-401. doi: 10.1097/GCO.0000000000000820. Epub 2022 Aug 17.

Abstract

Purpose of review: Our objective is to review the currently available literature on the use of platelet-rich plasma (PRP) in patients with pelvic floor disorders and to critically appraise the latest evidence on the safety and efficacy of the PRP application.

Recent findings: The evidence on the use of PRP for the treatment of stress urinary incontinence (SUI) appears promising, although limited to case series, case reports and animal studies. PRP has also been proposed to enhance the surgical outcomes of pelvic organ prolapse (POP) by native tissue repair with promising success rates. The application of PRP in other PFDs including vaginal fistulas, genitourinary syndrome of menopause (GSM), mesh exposure and lichen sclerosus has been also associated with beneficial outcomes and a favorable safety profile.

Summary: The currently available literature indicates that PRP could have a beneficial effect as a single or adjuvant treatment in patients with SUI, POP, GSM, vaginal fistula and genital lichen sclerosus with minimal adverse events. However, valid evidence is still lacking and further well-designed studies are warranted in the field to confirm the validity of the so far reported outcomes.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Lichen Sclerosus et Atrophicus* / complications
  • Pelvic Organ Prolapse* / surgery
  • Platelet-Rich Plasma*
  • Surgical Mesh / adverse effects
  • Urinary Incontinence, Stress* / etiology
  • Urinary Incontinence, Stress* / therapy